What is Micreos?
Micreos is at the forefront of dermatological innovation, developing engineered endolysin technology to combat pathogens such as Staphylococcus aureus, a common exacerbator of chronic skin diseases. Based in Zug, Switzerland, the company's proprietary platform targets harmful bacteria while preserving the delicate skin microbiome. This targeted approach aims to address significant unmet medical needs in the dermatology sector, positioning Micreos as a key player in the development of next-generation therapeutic solutions.
How much funding has Micreos raised?
Micreos has raised a total of $108.6M across 4 funding rounds:
Private Equity
$13.4M
Unspecified
$33.8M
Unspecified
$37.1M
Other Financing Round
$24.4M
Private Equity (2016): $13.4M, investors not publicly disclosed
Unspecified (2019): $33.8M led by Undisclosed
Unspecified (2021): $37.1M, investors not publicly disclosed
Other Financing Round (2022): $24.4M, investors not publicly disclosed
What's next for Micreos?
With a substantial funding base and a clear strategic direction, Micreos is poised for its next phase of growth. The company's focus on advancing its lead molecule, MEndoB, towards clinical trials in late 2026 indicates a strong commitment to product development and market entry. This enterprise-level backing suggests confidence in Micreos's technology and its potential to revolutionize dermatological care. The company is actively seeking strategic partnerships to accelerate its mission of transforming treatments for chronic skin conditions.
See full Micreos company page
